Abstract:
Polymer microspheres for embolizing blood vessels and optionally delivering therapeutic agents are provided. The microspheres include PLGA 50:50 and/or Ptx, and are generally formed by emulsion means.
Abstract:
In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.
Abstract:
A medical device having a polymer-free outer surface layer comprising a crystalline drug selected from the group consisting of everolimus, tacrolimus, sirolimus, zotarolimus, biolimus, and rapamycin. The device may be produced by a method comprising the steps of providing a medical device; applying a solution of the drug to said portion of the outer surface to form a coating of amorphous drug; and vapor annealing the drug with a solvent vapor to form crystalline drug; wherein a seed layer of a crystalline form of said drug having a maximum particle size of about 10 μm or less is applied to at least said portion of the outer surface of the device before or after applying the drug solution, but before vapor annealing the amorphous coating.
Abstract:
In one aspect, the present disclosure pertains to lubricous coating compositions that comprise (a) a higher molecular weight polyvinylpyrrolidone, (b) a lower molecular weight polyvinylpyrrolidone, and (c) a polyfunctional unsaturated crosslinking agent. In some embodiments, such lubricous coating compositions are present in crosslinked form on the surface of a medical article. In some embodiments, the lubricous coating compositions further comprise a solvent, in which case such compositions may be, for example, applied to a substrate in the form of a layer and subsequently crosslinked, thereby forming a lubricious coating on the substrate. In another aspect, the present disclosure is directed to methods for forming various medical articles.
Abstract:
A medical device may be coated with a therapeutic composition that includes a direct oral anticoagulant. An illustrative drug coating composition may comprise an excipient including polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), or poly(vinylidene fluoride)-co-hexafluoropropylene (PVDF-HFP) and a direct oral anticoagulant (DOAC). The illustrative drug coating may be applied to an outer surface of a medical device.
Abstract:
An occlusive implant includes an expandable framework that is configured to shift between a collapsed configuration and an expanded configuration. An occlusive member is disposed along at least a portion of the expandable framework. At least part of the occlusive implant is configured to repel fibrinogen. In some cases, the occlusive implant may be configured for placement within a left atrial appendage (LAA) of a patient's heart.
Abstract:
Polymer microspheres for embolizing blood vessels and optionally delivering therapeutic agents are provided. The microspheres include PLGA 50:50 and/or Ptx, and are generally formed by emulsion means.
Abstract:
An occlusive implant includes an expandable framework that is configured to shift between a collapsed configuration and an expanded configuration. An occlusive member is disposed along at least a portion of the expandable framework. At least part of the occlusive implant is configured to repel fibrinogen. In some cases, the occlusive implant may be configured for placement within a left atrial appendage (LAA) of a patient's heart.
Abstract:
A catheter system includes a catheter having a first balloon and a second balloon. The first balloon is longitudinally offset from the second balloon along the length of the catheter. The first and second balloons both have expanded and unexpanded states. The second balloon has a drug coating. The catheter system has a first configuration, a second configuration, and a third configuration. In the first configuration, the first balloon is in the unexpanded state and the second balloon is in the unexpanded state. In the second configuration, the first balloon is in the expanded state and the second balloon is in the unexpanded state. In the third configuration, the first balloon is in the expanded state and the second balloon is in the expanded state.